Relay Therapeutics (RLAY) Other Operating Expenses (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Other Operating Expenses data on file, last reported at -$11.4 million in Q2 2024.

• On a quarterly basis, Other Operating Expenses fell 428.53% year-over-year to -$11.4 million in Q2 2024; TTM through Mar 2025 was -$11.4 million, a 56.86% decrease from a year earlier, with the FY2024 full-year figure at -$13.2 million, down 105.64% from the prior year.
• Other Operating Expenses for Q2 2024 stood at -$11.4 million, down from -$1.8 million in the prior quarter.
• Over the last five years, Other Operating Expenses for RLAY reached as high as $134.9 million in Q2 2021 and fell as low as -$11.4 million in Q2 2024.
• Historically, Other Operating Expenses has averaged $8.2 million across 4 years, with a median of -$1.2 million in 2023.
• Across the five-year window, Other Operating Expenses sank 1361.24% in 2022 and surged 80.4% in 2023, its largest moves.
• Year by year, Other Operating Expenses stood at $836000.0 in 2021, then sank by 1361.24% to -$10.5 million in 2022, then jumped by 80.4% to -$2.1 million in 2023, then tumbled by 450.27% to -$11.4 million in 2024.
• Per Business Quant data, the three most recent Other Operating Expenses figures were -$11.4 million in Q2 2024, -$1.8 million in Q1 2024, and -$2.1 million in Q4 2023.